NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

According to Dr Asif Ahmed, an NHS GP , if you have pain, fatigue or visual problems, which worsen in hot weather, it could ...

Objective To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

Since 2014, several immunomodulatory approaches that have modest but clinically meaningful effects have been approved for the management of progressive multiple sclerosis, primarily for people who ...

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

SPMS can cause mobility and balance issues, but you can maintain your independence and safety with these expert-backed home ...

Key TakeawaysA new type of AI can help track a person’s multiple sclerosisThe AI correctly judged with 90% accuracy when MS ...

In relapsing-remitting MS, which 80 to 85 percent of people are initially diagnosed with, symptom flares come and go. In time, RRMS progresses to secondary-progressive MS, where relapses occur ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod.